Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DOV Ocinaplon Phase III Anxiety Trial On Hold Again Over Liver Function Tests

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

DOV's internal review of Phase III safety data on its anxiolytic ocinaplon will take "several months" and could result in a reduced dosing regimen

You may also be interested in...



DOV drops ocinaplon

DOV is discontinuing development of its GABA receptor agonist ocinaplon "due to an unacceptable rate of liver enzyme elevations," the firm says Oct. 28. Ocinaplon, which had been in development for generalized anxiety disorder, had experienced several clinical holds, the most recent occurring in August (1Pharmaceutical Approvals Monthly September 2005, p. 15). "DOV will select a follow-on candidate from one of the backup compounds in its preclinical program," the company says. The firm also confirmed plans to submit an NDA for use of its non-opioid analgesic bicifadine in chronic low back pain during the first half of 2007. Phase II studies in osteoarthritis and neuropathic pain are slated to begin in the fourth quarter of 2005; an acute pain sNDA is slated for the fourth quarter of 2007...

Pfizer/Neurocrine indiplon resubmission

Merck's human papillomavirus vaccine Gardasil shows a higher efficacy rate in adolescents (male and female) aged 10 to 15 than in young women aged 16 to 23, according to a Phase III study presented May 19 at the European Society of Pediatric Infectious Diseases. In the 1,529-patient trial, seroconversion rates in the combined adolescent cohort (506 female, 510 male) were 100% for HPV types 16, 6 and 11, and 99.9% for HPV 18. Results were identical in the 513 16-23-year old women, except for serotype 18, for which Gardasil produced a 99.1% conversion rate. The study comes on the heels of a Phase II trial published in the April issue of Lancet Oncology, in which the quadrivalent vaccine was shown to significantly reduce the combined incidence of persistent HPV 16, 18, 6 or 11 compared to placebo. Merck plans to file a Gardasil BLA in the second half of 2005 (1Pharmaceutical Approvals Monthly May 2005, In Brief)...

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

PS003031

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel